Europe Non-Alcoholic Steatopatitis Market

The Europe non-alcoholic steatopatitis market is expected to reach US$ 6,765.21 million by 2028 from US$ 496.83 million in 2021. The market is estimated to grow at a CAGR of 45.2% from 2021 to 2028.

Non-Alcoholic Steatopatitis is an under-recognized condition. Increasing awareness of this disease among the general public and primary care physicians (PCPs) is essential for a structured referral pathway and early detection. By establishing a clear patient pathway for referrals and patient awareness campaigns, more individuals can be identified and sent to specialists for further evaluation, thereby expanding the patient pool. To raise awareness of NASH, the NASH Education Program launched the public education campaign on June 12, 2018, on "International NASH Day" to raise awareness of the non-alcoholic fatty liver disease and its more advanced form NASH, which affects over ~115 million people. NASH 24X7, a digital platform aimed at raising exposure and awareness regarding the epidemic NASH, took a few steps on June 12, 2019, on International NASH Day, including HCP support, patient awareness, and press/TV release programs. In terms of patient education, NASH Crusaders of NASH 24X7 collaborated with HCPs across India to hold many small and large-scale awareness and education workshops on liver health and the necessity of a healthy lifestyle in preventing NAFLD/NASH. On International NASH Day, several efforts were made to reach the

general public, such as press releases and television programs using digital and print media. The Europe non-alcoholic steatopatitis market is expected to grow at a good CAGR during the forecast period.

Europe Non-Alcoholic Steatopatitis Revenue and Forecast to 2028 (US$ Million)

  

Europe Non-Alcoholic Steatopatitis Market Segmentation         

The Europe Non-Alcoholic Steatopatitis market segmented into product, application, sales channel, and country. Based on product type the Europe Non-Alcoholic Steatopatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period .Based on application the Europe Non-Alcoholic Steatopatitis market segmented into treatment and diagnosis. The treatment segment is dominated Europe Non-Alcoholic Steatopatitis market in 2020. Based on sales channel the Europe Non-Alcoholic Steatopatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated Europe Non-Alcoholic Steatopatitis market in 2020. Based on country, the Europe non-alcoholic steatopatitis market is segmented into Germany, the UK, France, Italy, Spain, and the rest of Europe. Germany dominated the Europe non-alcoholic steatopatitis market in 2020.

Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG, Galmed Pharmaceutical, GENFIT, ONE WAY LIVER SI, BioPredictive S.A.S, Siemens Healthineers AG, and Laboratory Corporation of America Holdings are among the leading companies in the Europe non-alcoholic steatopatitis market are among the leading companies in the Europe non-alcoholic steatopatitis market.